Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study

被引：0
|
作者：
Masand, Prakash [1 ]
Vieta, Eduard [1 ]
Waraich, Simranpreet [1 ]
Kramer, Ken [1 ]
Kerolous, Majid [1 ]
机构：
[1] AbbVie, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Cariprazine; Major Depressive Disorder; Depression; Adjunctive; Long-Term;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P343
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [41] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [42] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Michael E. Thase
    Arielle D. Stanford
    Asli Memisoglu
    William Martin
    Amy Claxton
    J. Alexander Bodkin
    Madhukar H. Trivedi
    Maurizio Fava
    Miao Yu
    Sanjeev Pathak
    Neuropsychopharmacology, 2019, 44 : 2268 - 2276
  • [43] Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
    Thase, Michael E.
    Stanford, Arielle D.
    Memisoglu, Asli
    Martin, William
    Claxton, Amy
    Bodkin, J. Alexander
    Trivedi, Madhukar H.
    Fava, Maurizio
    Yu, Miao
    Pathak, Sanjeev
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (13) : 2268 - 2276
  • [44] Sustained Efficacy With Long-Term Treatment With AXS-05: Results From the COMET Phase 3 Trial, a Long-Term, Open-Label Study Evaluating the Efficacy and Safety of AXS-05 for the Treatment of MDD
    O'Gorman, Cedric
    Jones, Amanda
    Tabuteau, Herriot
    ANNALS OF CLINICAL PSYCHIATRY, 2021, 33 (03) : 16 - 16
  • [45] Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
    Iwata, Nakao
    Ishigooka, Jun
    Naoi, Ichiro
    Matsumoto, Masahiro
    Kanamori, Yuichi
    Nakamura, Hiroshi
    Higuchi, Teruhiko
    CNS DRUGS, 2020, 34 (01) : 103 - 116
  • [46] Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
    Nakao Iwata
    Jun Ishigooka
    Ichiro Naoi
    Masahiro Matsumoto
    Yuichi Kanamori
    Hiroshi Nakamura
    Teruhiko Higuchi
    CNS Drugs, 2020, 34 : 103 - 116
  • [47] A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
    Garcia-Borreguero, Diego
    Grunstein, Ronald
    Sridhar, Guruswamy
    Dreykluft, Tilman
    Montagna, Pasquale
    Dom, Rene
    Lainey, Eric
    Moorat, Anne
    Roberts, James
    SLEEP MEDICINE, 2007, 8 (7-8) : 742 - 752
  • [48] Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (06) : 445 - 453
  • [49] Open-label assessment of the long-term tolerability, safety, and efficacy of sertindole in patients with schizophrenia
    Hale, T.
    Murray, R. M.
    Azorin, J. M.
    Maehlum, E.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 431 - 432
  • [50] LONG-TERM SAFETY AND EFFICACY OF BIOSIMILAR INFLIXIMAB (CT-P13) AFTER SWITCHING FROM ORIGINATOR INFLIXIMAB: RESULTS FROM THE 26-WEEK OPEN LABEL EXTENSION OF A NORWEGIAN RANDOMISED TRIAL
    Goll, G. L.
    Jorgensen, K. K.
    Sexton, J.
    Olsen, I. C.
    Bolstad, N.
    Lorentzen, M.
    Haavardsholm, E. A.
    Mork, C.
    Jahnsen, J.
    Kvien, T. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1383 - 1384
12345